Systematic Reviews of Animal Experiments Demonstrate Poor Human Clinical and Toxicological Utility
The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Abstract
The assumption that animal models are reasonably predictive of human outcomes provides the basis for their widespread use in toxicity testing and in biomedical research aimed at developing cures for human diseases. To investigate the validity of this assumption, the comprehensive Scopus biomedical bibliographic databases were searched for published systematic reviews of the human clinical or toxicological utility of animal experiments. In 20 reviews in which clinical utility was examined, the authors concluded that animal models were either significantly useful in contributing to the development of clinical interventions, or were substantially consistent with clinical outcomes, in only two cases, one of which was contentious. These included reviews of the clinical utility of experiments expected by ethics committees to lead to medical advances, of highly-cited experiments published in major journals, and of chimpanzee experiments--those involving the species considered most likely to be predictive of human outcomes. Seven additional reviews failed to clearly demonstrate utility in predicting human toxicological outcomes, such as carcinogenicity and teratogenicity. Consequently, animal data may not generally be assumed to be substantially useful for these purposes. Possible causes include interspecies differences, the distortion of outcomes arising from experimental environments and protocols, and the poor methodological quality of many animal experiments, which was evident in at least 11 reviews. No reviews existed in which the majority of animal experiments were of good methodological quality. Whilst the effects of some of these problems might be minimised with concerted effort (given their widespread prevalence), the limitations resulting from interspecies differences are likely to be technically and theoretically impossible to overcome. Non-animal models are generally required to pass formal scientific validation prior to their regulatory acceptance. In contrast, animal models are simply assumed to be predictive of human outcomes. These results demonstrate the invalidity of such assumptions. The consistent application of formal validation studies to all test models is clearly warranted, regardless of their animal, non-animal, historical, contemporary or possible future status. Likely benefits would include, the greater selection of models truly predictive of human outcomes, increased safety of people exposed to chemicals that have passed toxicity tests, increased efficiency during the development of human pharmaceuticals and other therapeutic interventions, and decreased wastage of animal, personnel and financial resources. The poor human clinical and toxicological utility of most animal models for which data exists, in conjunction with their generally substantial animal welfare and economic costs, justify a ban on animal models lacking scientific data clearly establishing their human predictivity or utility.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, Knight (72) could find no review of animal research studies that rated a majority of the experiments as having “good” methodological quality.”
From Limitations of Animal Studies for Predicting Toxicity in Clinical Trials (2019) · cites this paper as [72]
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807 · cited 1×
“5% (8/76) of these medical interventions were subsequently approved for use in patients, and, as stated previously, even in these cases, human benefit cannot be assumed, because adverse reactions to approved interventions are common, and a leading cause of death (46).”
BackgroundEvidence-Based Medicine: A New Approach to Teaching the Practice of Medicine
Guyatt, G. (1992) · JAMA · doi:10.1001/jama.1992.03490170092032 · Cited by 4,202
Heroux, J., & Gharib, A. M. (2008) · Molecular Imaging in Oncology · doi:10.3109/9781420019957-3 · Cited by 2,187
1,026 Experimental treatments in acute stroke
O'Collins, V. E., Macleod, M. R., Donnan, G. A., Horky, L. L., van der Worp, B. H., & Howells, D. W. (2006) · Annals of Neurology · doi:10.1002/ana.20741 · Cited by 1,460
National Center for Biotechnology Information
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_301184 · Cited by 1,400
Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug Development
(1999) · Stroke · doi:10.1161/01.str.30.12.2752 · Cited by 1,251
Chen, Z.-M. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04010-5 · Cited by 1,232
Research works printed but not linked: 40
- Goldberg A.M., 2002, ALTEX, 19, 137
- Stephens M.L., 2002, Developments in Biologicals, 111, 213
- O'Shea D., 2000, Johns Hopkins enters suit over lab animal regulations.
- Sauer U.G., 2005, ALTEX, 22, 233
- Rusche B., 2003, ALTEX, 20, 63
- Combes R.D., 2004, ATLA, 32, 635
- Green S., 2004, ATLA, 32, 359
- Louekari K., 2006, ATLA, 34, 377
- Sandusky C., 2006, ALTEX, 23, 150
- Brom F.W., 2002, ALTEX, 19, 78
- Festing M.F.W., 2004, ATLA, 32, 733
- Pawlik W.W., 1998, Folia Medica Cracoviensia, 39, 175
- Kjellmer I., 2002, Lakartidningen, 99, 1172
- SingerP. (1990). Animal Liberation: A New Ethics for our Treatment of Animals, 2nd edn, 320 pp. New York, NY, USA: New York Review/Random House.
- Bhogal N., 2006, ATLA, 34, 225
- 10.1001/jama.1993.03510160055029 · doi:10.1001/jama.1993.03510160055029
- Villar D., 1998, Veterinary & Human Toxicology, 40, 156
- Lindl T., 2005, ALTEX, 22, 143
- Lindl T., 2006, ALTEX, 23, 111
- Conlee K.M., 2004, ATLA, 32, 315
- Knight A., 2006, ATLA, 34, 19
- Tomatis L., 1993, New Frontiers in Cancer Causation, 371
- Ashby J., 1993, Carcinogenesis, 8, 489
- Balcombe J., 2004, Contemporary Topics in Laboratory Animal Science, 43, 42
- Knight A., 2006, ATLA, 34, 29
- Balls M., 2004, ATLA, 32, 1
- Festing M.F.W., 2004, ATLA, 32, 133
- De Boo J., 2005, ATLA, 33, 369
- van Wilgenburg H., 2004, ATLA, 32, 607
- Eskola S., 1999, Scandinavian Journal of Laboratory Animal Science, 26, 134
- Festing M.F.W., 1998, ATLA, 26, 283
- Balls M., 1995, ATLA, 23, 838
- Arlt S., 2005, Deutsche Tierärztliche Wochenschrift, 112, 146
- Sauer U.G., 2006, ALTEX, 23, 3
- Balls M., 1995, ATLA, 23, 129
- Balls M., 2005, ATLA, 33, 299
- Curren R.D., 1995, ATLA, 23, 211
- Balls M., 2006, ALTEX, 23, 332
- Balls M., 1995, ATLA, 23, 884
- Balls M., 2004, ATLA, 32, 755
Cited by
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.008 · Cited by 732
“Indeed, Knight (72) could find no review of animal research studies that rated a majority of the experiments as having “good” methodological quality.”
BackgroundLook back in anger – what clinical studies tell us about preclinical work
Hartung, T. (2013) · ALTEX · doi:10.14573/altex.2013.3.275 · Cited by 200
A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans
Clark, M., & Steger-Hartmann, T. (2018) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2018.04.018 · Cited by 162
Millifluidic culture improves human midbrain organoid vitality and differentiation
Berger, E., Magliaro, C., Paczia, N., Monzel, A. S., Antony, P., Linster, C. L., Bolognin, S., Ahluwalia, A., & Schwamborn, J. C. (2018) · Lab on a Chip · doi:10.1039/c8lc00206a · Cited by 150
Synthetic or food-derived vitamin C—Are they equally bioavailable?
Carr, A., & Vissers, M. (2013) · Nutrients · doi:10.3390/nu5114284 · Cited by 137
“Thus, not only do the reviewed studies reiterate the injunction that the findings of animal studies should not be directly translated to humans [98,99], but it is also apparent that additional comparative bioavailability studies in humans are unwarranted.”
Metadata
- Authors
- Knight, A.
- Affiliations
- Animal Consultants International, London, UK
- Corresponding author
- Knight, Andrew
- Venue
- Alternatives to Laboratory Animals
- Publisher
- SAGE Publications
- Published
- 2007-12
- Volume
- 35
- Issue
- 6
- Pages
- 641-659
- ISSN
- 0261-1929 (ISSN-L)
- 2632-3559
- OpenAlex
- W2112018944
- Cited by
- 105
- References
- 128
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 6 · 2023: 6 · 2022: 6 · 2021: 7 · 2020: 5 · 2019: 4 · 2018: 8 · 2017: 9 · 2016: 5 · 2015: 3 · 2014: 2 · 2013: 6 · 2012: 2
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Alternatives to Laboratory Animals (publishedVersion)
- PubMed (publishedVersion)
- Murdoch University Research Portal (submittedVersion)
- WBI Studies Repository (submittedVersion)
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- animal models, predictive validity, clinical utility, species differences, carcinogenicity, teratogenicity, model validation, animal welfare, alternatives to animal testing
- MeSH terms
- Animals, Animal Testing Alternatives, Antibodies, Monoclonal, Pan troglodytes, Clinical Trials as Topic, Craniocerebral Trauma, Humans, Toxicology, Reproducibility of Results, Treatment Outcome, Stroke, Models, Animal, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic Reviews of Animal Experiments Demonstrate Poor Human Clinical and Toxicological Utility. https://app.cochat.ai/papers/10.1177/026119290703500610
- The paper
- Knight, A. (2007). Systematic Reviews of Animal Experiments Demonstrate Poor Human Clinical and Toxicological Utility. Alternatives to Laboratory Animals. https://doi.org/10.1177/026119290703500610
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.